Startup profile for Traitomic: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Traitomic funding, valuation and investors

Carlsberg-origin plant and microbial trait discovery business using FIND-IT to select genetic variants without direct genome editing.

Verified company research · funding, investors and latest developments

Keep track of Traitomic

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

€20M · November 17, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Copenhagen, Denmark

Investors in latest funding

Lead: Sofinnova Partners

Other: Export and Investment Fund of Denmark (EIFO) , Footprint Firm , PSV Hafnium , Nordic Foodtech VC , SVG Ventures

Sources: latest funding · abgsc.com Last verified: 2026-11-18

Overview

Traitomic commercializes FIND-IT, a targeted genetic-variation and screening process developed at Carlsberg Research Laboratory. It supports crop and microorganism customers seeking specific useful traits through conventional-breeding approaches. It selects and validates variants in genetic libraries, then hands over relevant biological material and information for further development.

Contract prices, development cycles, per-trait economics, regulatory status by geography and valuation are undisclosed.

Why Traitomic is interesting

A €20M Series A led by Sofinnova on November 17 funds a non-GM route to valuable plant and microbial variants, with biological material delivery to customers rather than a consumer seed marketplace. The financier and deal adviser corroborate its first external financing.

Product & use cases

Representative customer engagement described in Traitomic's own guide: (1) a breeder or biotech producer defines a desired outcome and source organism; (2) scientists agree a Traitomic Plan of Approach and whether to use customer biological material or an established library; (3) FIND-IT identifies targeted variants through a controlled-variation and screening process; (4) Traitomic isolates promising seeds, plants or strains; (5) partners evaluate the genetic change and phenotype against commercial objectives; (6) genetic information and biological material are transferred for customer's own validation, scale-up and commercialization. This is a sourced process description, not independent testing or a claim all projects achieve the target.

  • Plant breeders: find naturally occurring variants associated with desired agronomic or quality traits.
  • Food and fermentation firms: select microbial strains with targeted production properties.
  • Industrial biotech companies: screen organisms before later scale-up and regulatory checks.

Key facts

  • €20M Series A disclosed 17 November 2026, led by Sofinnova Partners with EIFO, Footprint Firm, PSV Hafnium, Nordic Foodtech VC and SVG Ventures participating.
  • ABG Sundal Collier says it advised Carlsberg Group on the transaction, corroborating the issuer's disclosure.
  • Company materials describe targeted genetic screening, isolation and biological-material transfer—not CRISPR editing of customer varieties.
  • Third-party coverage reports 116 traits delivered to 47 customers across 32 organisms; these remain reported operating metrics, not audited revenue or successful downstream market launches.
  • Traitomic originated from Carlsberg's breeding research; separate Carlsberg brewing IP and licence scope should not be inferred beyond public statements.

Funding history (newest first)

Series A

2026-11-17 €20M
  • Sofinnova Partners (lead)
  • Export and Investment Fund of Denmark (EIFO) (participant)
  • Footprint Firm (participant)
  • PSV Hafnium (participant)
  • Nordic Foodtech VC (participant)
  • SVG Ventures (participant)

Source: Read source · abgsc.com

Investors in our directory

Funds linked from Traitomic's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Potentially useful for companies seeking trait discovery without directly engineering the final genome; however, regulation of novel varieties and microorganisms differs by jurisdiction and production pathway. The vendor has not published a universal time-to-trait, success rate, customer ROI or per-project price.

Procurement should compare target genetic variants found, validated phenotype, time to breed into production material, freedom to operate and licensing/ownership of strains. Vendor-reported delivered trait counts do not reveal downstream commercial adoption or regulatory clearance.

  • KeyGene direct

    Plant genomics and breeding technology specialist; compare trait discovery and breeding services.

  • Inari Agriculture adjacent

    Gene-editing-led seed improvement; fundamentally different regulatory and IP tradeoffs.

  • Pairwise adjacent

    CRISPR-enabled crop trait development; compare desired trait and go-to-market pathway.

  • In-house mutagenesis and screening alternative

    Traditional in-house R&D may offer greater IP control with higher lab capacity needs.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Traitomic

Practical answers founders, operators, and investors typically search for.

The company describes FIND-IT as controlled genetic variation with targeted screening and traditional breeding approaches, not direct gene editing. Product regulatory treatment remains jurisdiction- and trait-specific.
Yes, the transaction adviser corroborates a €20M Series A announced on November 17, 2026; it does not disclose valuation.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.